Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study

Xia, DD; Bai, W; Wang, EX; Li, JP; Chen, XM; Wang, ZX; Huang, MS; Huang, M; Sun, JH; Yang, WZ; Lin, ZY; Wu, JB; Li, ZX; Yang, SF; Zhu, X; Chen, ZZ; Zhang, YF; Fan, WZ; Mai, QC; Ding, R; Nie, CH; Feng, L; Li, XD; Huang, WK; Sun, J; Wang, QH; Lv, Y; Li, XM; Luo, BH; Wang, ZY; Yuan, J; Guo, WG; Li, K; Li, B; Li, RJ; Yin, ZX; Xia, JL; Han, GH

Han, GH (通讯作者),Northwest Univ, Digest Dis Hosp, Xian Int Med Ctr Hosp, Dept Liver Dis & Intervent Radiol, Xian, Peoples R China.;Han, GH (通讯作者),Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, Dept Liver Dis & Digest Intervent Radiol, Xian, Peoples R China.;Han, GH (通讯作者),Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Peoples R China.

LIVER CANCER, 2022; 11 (4): 368

Abstract

Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvati......

Full Text Link